Citizens JMP lowered the firm’s price target on Viridian Therapeutics (VRDN) to $38 from $42 and keeps an Outperform rating on the shares. Viridian reported Q1 results and reiterated that it remains on track to submit the veligrotug Biologics License Application for thyroid eye disease in the second half of 2025, the analyst tells investors in a research note. Additional clinical catalysts remain on track, and the company is well-funded to execute on broad development activities, the firm says.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics Reports Q1 2025 Progress and Financials
- Viridian Therapeutics: Strong Financials and Promising Pipeline Justify Buy Rating
- Buy Rating for Viridian Therapeutics: Strong Pipeline and Financial Position Drive Strategic Advancements
- Viridian Therapeutics: Promising Outlook with Strong Pipeline and Regulatory Progress
- Viridian Therapeutics, Inc. (VRDN) Q1 Earnings Cheat Sheet